SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| MITCHELL ROBERT BRIAN | EVP, General Counsel and CRO | 2026-08-07 | Option exercise | 23000 | $2.4M |
| MITCHELL ROBERT BRIAN | EVP, General Counsel and CRO | 2026-08-07 | Open-market sell | 11454 | $2.1M |
| MITCHELL ROBERT BRIAN | EVP, General Counsel and CRO | 2026-08-07 | Open-market sell | 10529 | $1.9M |
| MITCHELL ROBERT BRIAN | EVP, General Counsel and CRO | 2026-08-07 | Open-market sell | 1017 | $188K |
| Darden James Matthew | Co-Chairman & CEO, Director | 2026-07-31 | Option exercise | 50000 | $4.9M |
| Darden James Matthew | Co-Chairman & CEO, Director | 2026-07-31 | Open-market sell | 49600 | $9.0M |
| Darden James Matthew | Co-Chairman & CEO, Director | 2026-07-31 | Open-market sell | 400 | $73K |
| Kalmbach Thomas Peter | EVP & CFO | 2026-07-30 | Option exercise | 10000 | $1.0M |
| Kalmbach Thomas Peter | EVP & CFO | 2026-07-30 | Option exercise | 11000 | $1.3M |
| Kalmbach Thomas Peter | EVP & CFO | 2026-07-30 | Open-market sell | 10720 | $1.9M |
| Kalmbach Thomas Peter | EVP & CFO | 2026-07-30 | Open-market sell | 4840 | $872K |
| Kalmbach Thomas Peter | EVP & CFO | 2026-07-30 | Open-market sell | 2650 | $480K |
| Kalmbach Thomas Peter | EVP & CFO | 2026-07-30 | Open-market sell | 2790 | $507K |
| MAJORS MICHAEL CLAY | EVP - Chief Strategy Officer | 2026-07-29 | Option exercise | 37000 | $3.8M |
| MAJORS MICHAEL CLAY | EVP - Chief Strategy Officer | 2026-07-29 | Open-market sell | 33500 | $6.0M |
| MAJORS MICHAEL CLAY | EVP - Chief Strategy Officer | 2026-07-29 | Open-market sell | 3500 | $628K |
| Kalmbach Thomas Peter | EVP & CFO | 2026-07-28 | Option exercise | 14100 | $1.7M |
| Kalmbach Thomas Peter | EVP & CFO | 2026-07-28 | Option exercise | 11550 | $1.5M |
| Kalmbach Thomas Peter | EVP & CFO | 2026-07-28 | Open-market sell | 9550 | $1.7M |
| Kalmbach Thomas Peter | EVP & CFO | 2026-07-28 | Open-market sell | 12303 | $2.2M |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
A short-seller campaign has metastasized into active securities class action and derivative litigation across six lawsuits, materially raising legal liability and defense costs. Simultaneously, new disclosures of a $1.2B Bermuda reinsurance cession and alternative investment exposure introduce concrete capital adequacy and liquidity risks that could impair dividend capacity. AI risk has been elevated to explicit management responsibility, rounding out a broad but sub-existential deterioration across legal, liquidity, and technology themes.
4 company-specific · 1 common-mode
Short seller campaign escalated from exposure to litigation to actual putative securities class action and derivative shareholder litigation with cross-reference to Note 5 contingencies.
We have become subject to, and may in the future be subject to, short selling strategies driving down the market price of our common stock. Short selling is the practice of selling securities that…
Litigation exposure escalated materially: from one putative class action to one class action plus five shareholder derivative lawsuits. Increased legal liability and defense costs.
Legal, Regulatory, and Compliance Risks Recent volatility in the trading price of our common stock has and can be expected to result in securities class action litigation. In April 2024, the trading…
New disclosure of material alternative investment exposure with explicit liquidity and regulatory capital risks that could impair dividend capacity and overall liquidity.
Our investment portfolio contains certain alternative investments that may be illiquid and volatile, which could negatively affect our investment income and liquidity. Over the past several years, we…
New disclosure of $1.2B reinsurance cession to Bermuda subsidiary and regulatory risk that could require additional capital contributions to holding company.
Our ability to fund operations is substantially dependent on available funds from our insurance subsidiaries. As a holding company with no direct operations, our principal asset is the capital stock…
AI risk elevated from emerging technology to explicit management responsibility. New disclosure of "increasingly complex AI risks" alongside cyberattacks signals escalated concern.
General Risk Factors The failure to maintain effective information systems or manage responsible use of emerging technologies, including artificial intelligence, could adversely affect our financial…
David A. Rodriguez retired from the Board of Directors of Globe Life Inc. effective immediately on August 4, 2026. The disclosure centers on a director's departure for personal reasons, with explicit statement that it was not due to disagreement with the Company. This is a clear executive departure event under Item 5.02(b), and board changes are material to investors assessing governance and leadership continuity.
View raw filing on EDGAR →Globe Life Inc. issued a press release on July 22, 2026 announcing second quarter 2026 financial results, disclosing net income of $3.65 per diluted share (up 20% year-over-year), net operating income of $3.61 per share (up 10%), and increased full-year 2026 earnings guidance to $15.55–$15.95. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the earnings release incorporated as Exhibit 99.1, which is the standard disclosure mechanism for quarterly earnings announcements.
View raw filing on EDGAR →Globe Life entered into two material credit agreements on June 26, 2026: a Third Amended and Restated Credit Agreement (extending maturity to June 26, 2031 and changing administrative agents) and an Amended and Restated Term Loan Agreement (increasing principal from $250 million to $450 million and extending maturity to June 26, 2029). These amendments to existing credit facilities constitute material amendments to direct financial obligations, with the term loan increase representing a $200 million expansion of borrowing capacity. This is disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and materially affects the registrant's capital structure and liquidity position.
View raw filing on EDGAR →